Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer

Table 2 Result of chemotherapy response of each regimen, n (%)

	GA (n = 54)	FOLFIRINOX (n = 47)	P value
Best response			0.216
PR	10 (18.5)	5 (10.6)
SD	35 (64.8)	31 (66.0)
PD	9 (16.7)	11 (23.4)
DCR (PR + SD)	45 (83.3)	36 (76.6)	0.402
Dose reduction	41 (75.9)	32 (68.1)	0.385
Delivery dose (%)	78.9 ± 16.5	87.3 ± 11.6	0.005b
Total over 80% dose	24 (44.4)	30 (65.2)	0.038a
Duration of chemotherapy (mo)	2.33 (1.43-3.24)	1.63 (1.19-2.08)	0.005b
Progression free survival (mo)	6.43 (4.43-8.43)	4.90 (4.44-5.36)	0.058
Overall survival (mo)	10.17 (6.03-14.31)	6.93 (5.32-8.54)	0.008b
2nd Chemotherapy	24 (44.4)	19 (40.4)	0.687
TS-1	15 (27.8)	1 (2.1)
Gemcitabine mono	0 (0)	12 (25.5)
GA	0 (0)	5 (10.6)
FOLFIRINOX	3 (5.6)	0 (0)
Onyvide	1 (1.9)	0 (0)
5-FU base	5 (9.3)	1 (2.1)
2nd chemotherapy PFS (mo)	3.23 (2.55-3.91)	2.70 (1.56-3.84)	0.191

^aP < 0.05,

^bP < 0.01, mean ± SD; median (95%CI). GA: Gemcitabine plus nab-paclitaxel; PR: Partial response; SD: Stable disease; PD: Progression disease; DCR: Disease control rate; TS-1: Tegafur/gimeracil/oteracil; 5-FU: 5-fluorouracil; PFS: Progression-free survival.